Journal
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.667879
Keywords
CRISPR; Cas13d; CasRx; RNA editing; VEGF (Vascular endothelial growth factor); AAV (Adeno-associated virus)
Categories
Funding
- National Health and Medical Research Council of Australia [GNT1185600]
- Shenzhen Key Laboratory of Biomimetic Materials and Cellular Immunomodulation [ZDSYS20190902093409851]
Ask authors/readers for more resources
Specific changes in the genome have been achieved by the revolutionary gene-editing tool CRISPR/Cas system, with CasRx, a member of the Cas13d family, showing great therapeutic potential in RNA editing. The programmable RNA editing CRISPR/Cas nucleases have made gene editing safer and more precise.
Specific changes in the genome have been accomplished by the revolutionary gene-editing tool known as clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system. The advent of programmable RNA editing CRISPR/Cas nucleases has made this gene-editing tool safer and more precise. Specifically, CasRx, a family member of the Cas13d family, has shown great therapeutic potential. Here, we describe the in vitro methods of utilizing this powerful RNA editing platform and determine the RNA editing efficiencies for CasRx with different forms of guide RNAs (also known as gRNA or sgRNA).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
